Igyxos Biotherapeutics Reports Positive Phase 1 Results for IGX12, First-in-Class Monoclonal Antibody Targeting Male and Female Infertility
核心洞察
Igyxos Biotherapeutics (搜索) successfully completed Phase 1 trials of IGX12, a first-in-class monoclonal antibody designed to enhance follicle-stimulating hormone efficacy for treating both male and female infertility.
The Multiple Ascending Dose study in 14 healthy male volunteers demonstrated excellent safety with no serious adverse events and favorable pharmacokinetics supporting potential monthly dosing.
IGX12 represents a novel approach to address male infertility, which accounts for nearly half of all infertility cases but currently has no approved treatments available.
Igyxos Biotherapeutics (搜索) announced the successful completion of its Phase 1 clinical trial evaluation of IGX12, a first-in-class potentiating monoclonal antibody designed to enhance follicle-stimulating hormone (FSH) efficacy for treating both male and female infertility. The French biotechnology company reported positive safety and pharmacokinetic results that support advancing the novel therapy to Phase 2 trials in 2026.
Phase 1 Trial Design and Results
The recent Multiple Ascending Dose (MAD) Phase 1 trial was a randomized, placebo-controlled study conducted in 14 healthy male volunteers. Participants received IGX12 at two dose levels (20 and 40 μg/kg) administered as subcutaneous injections every other week over a 6-week period, totaling 4 injections per participant.
The trial demonstrated an excellent safety profile at both dose levels, with no serious adverse events reported. The pharmacokinetic analysis revealed a gradual absorption phase and slow elimination half-life, characteristics that could support monthly dosing—an important consideration for fertility treatment regimens.
These results build upon the company's earlier Single Ascending Dose (SAD) study reported in March 2025, which evaluated IGX12 in 32 healthy volunteers (16 men and 16 women), providing comprehensive safety data across both male and female populations.
Mechanism of Action and Clinical Applications
IGX12 is engineered to enhance the potency and efficacy of follicle-stimulating hormone, a critical hormone involved in both female and male gametogenesis. The monoclonal antibody has been specifically designed to serve dual therapeutic purposes: improving ovarian stimulation in women undergoing medically assisted reproductive technologies and enhancing spermatogenesis in men with oligozoospermia, the medical term for low sperm count.
This dual-target approach addresses a significant unmet medical need, as male infertility accounts for nearly half of all infertility cases but currently has no approved treatment options available.
Clinical Development Timeline
Based on the positive Phase 1 results, Igyxos is planning to initiate Phase 2 trials in leading fertility centers across Europe in 2026. The company has positioned IGX12 as a potential breakthrough in reproductive medicine, representing the first significant innovation in infertility treatment in four decades.
Expert Commentary
Dr. Elke Bestel, Chief Medical Officer of Igyxos Biotherapeutics (搜索), emphasized the significance of the results: "There has been little innovation in the field of infertility over the last 40 years. Unlike current IVF treatment regimens, our innovative monoclonal antibody-based approach addresses both female and male infertility. Male infertility accounts for nearly half of all infertility cases and currently has no approved treatment. We are excited by these promising results, this time in exclusively male cohorts. Our goal is to bring a new treatment option for infertility to everyone that needs it."
Florent Ferré, Chief Executive Officer of Igyxos Biotherapeutics (搜索), added: "Following the results of our Single Ascending Dose study in March, these MAD study results are another important new milestone in the clinical development of our innovative approach to treating infertility. We are extremely encouraged by these positive Phase 1 results in both male and female cohorts."
Company Background
Founded in France in 2017, Igyxos Biotherapeutics (搜索) has raised over EUR 27 million in funding to support its innovative approach to infertility treatment. The funding includes EUR 19 million in equity from business angels and investors including Bpifrance via its Biotechnology Health Acceleration Fund, GO Capital, and UI Investissement, plus approximately EUR 8 million in grants, loans, and repayable advances from Bpifrance and regional funding bodies.